Document is current
Any future updates will be listed below
-
Authors
Tu, Shichun
Akhtar, Mohd Waseem
Escorihuela, Rosa Maria
Amador-Arjona, Alejandro
Swarup, Vivek
Parker, James https://orcid.org/0000-0002-1150-8374
Zaremba, Jeffrey D. https://orcid.org/0000-0001-6531-5474
Holland, Timothy
Bansal, Neha
Holohan, Daniel R.
Lopez, Kevin
Ryan, Scott D.
Chan, Shing Fai
Yan, Li
Zhang, Xiaofei
Huang, Xiayu
Sultan, Abdullah
McKercher, Scott R.
Ambasudhan, Rajesh
Xu, Huaxi
Wang, Yuqiang
Geschwind, Daniel H.
Roberts, Amanda J.
Terskikh, Alexey V.
Rissman, Robert A.
Masliah, Eliezer
Lipton, Stuart A.
Nakanishi, Nobuki
- License Information
-
More Information
Article History
Received: 16 December 2015
Accepted: 27 September 2017
First Online: 14 November 2017
Competing interests
: The authors declare that S.A.L. is the inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda<sup>®</sup>) to Forest Laboratories, Inc./Actavis/Allergan, Inc. The remaining authors declare no competing financial interests.
